Evidence map›Paper›PMID 40931753›Full record

ArticleOpen research Europe2025

Screening

Dina Al Nahhas, Sandra Marina Wellner, Margherita Sosio, Sonia I Maffioli, Salvatore Pisanu, Sergio Uzzau, Daniela Pagnozzi, Stefano Donadio, John Elmerdahl Olsen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open research Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ScreeningOpen research Europe · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dina Al Nahhas *Porto Conte Ricerche, Alghero, 07041, Italy.
Sandra Marina Wellner *Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, 1870, Denmark.
Margherita SosioNaicons, Milano, 20139, Italy.
Sonia I MaffioliNaicons, Milano, 20139, Italy.
Salvatore PisanuPorto Conte Ricerche, Alghero, 07041, Italy.
Sergio UzzauBiomedical Sciences, University of Sassari, Sassari, 07100, Italy.
Daniela PagnozziPorto Conte Ricerche, Alghero, 07041, Italy.
Stefano DonadioNaicons, Milano, 20139, Italy.ORCID https://orcid.org/0000-0002-2121-8979
John Elmerdahl OlsenVeterinary and Animal Sciences, University of Copenhagen, Frederiksberg, 1870, Denmark.ORCID https://orcid.org/0000-0001-6225-6587

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Innovative antibiotic discovery strategies are urgently needed to successfully combat infections caused by multi-drug-resistant bacteria. Methods: We employed a direct screening approach to identify compounds with antimicrobial and antimicrobial helper-drug activity against Gram-positive and Gram-negative bacteria. We used this platform in two different strains of methicillin-resistant Results: The antibiotics rifamycin O and thermorubin inhibited the growth of neomycin-resistant Conclusion: Compounds with antibacterial and helper drug activity were identified using our screening approach. The results demonstrate the importance of strain selection in antimicrobial screening and highlight the potential of natural products as a source of potential new antibacterial and adjuvant therapies against both Gram-positive and Gram-negative bacteria.

Indexed as

aminoglycosidesAntimicrobial screeningEscherichia coliMRSAnatural productspurification

Identifiers

PMID40931753
PMCPMC12417992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.